{
  "trial_id": "NCT01824290",
  "trial_group": "hypertension",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, weight, height, diagnosis of PAH, type of PAH (idiopathic, related to connective tissue disease, related to anorexigen use, associated with surgical repair), mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure, pulmonary vascular resistance (PVR), World Health Organization (WHO) functional class, use of endothelin receptor antagonist (ERA), aspartate transaminase (AST) levels, alanine transaminase (ALT) levels, use of conventional PAH medication, pregnancy status (for females of childbearing potential), history of left-sided heart disease, renal function (creatinine clearance), presence of retinal disorder, blood pressure (hypotension or hypertension status), presence of parenchymal lung disease, presence of bronchopulmonary dysplasia, concurrent phosphodiesterase type 5 (PDE5) inhibitor therapy, concurrent therapy with prostacyclin or its analogues, use of doxazosin, nitrates, or cancer therapy, use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers, nursing status, previous tadalafil therapy, allergy to excipients, participation in other clinical trials, ability to take orally administered tablets or suspension, diagnosis of Down syndrome.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "6 Minute Walk Distance",
          "6 Minute Walk Distance"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "diagnosis of PAH",
        "type of PAH (idiopathic, related to connective tissue disease, related to anorexigen use, associated with surgical repair)",
        "mean pulmonary artery pressure (mPAP)",
        "pulmonary artery wedge pressure",
        "pulmonary vascular resistance (PVR)",
        "World Health Organization (WHO) functional class",
        "use of endothelin receptor antagonist (ERA)",
        "aspartate transaminase (AST) levels",
        "alanine transaminase (ALT) levels",
        "use of conventional PAH medication",
        "pregnancy status (for females of childbearing potential)",
        "history of left-sided heart disease",
        "renal function (creatinine clearance)",
        "presence of retinal disorder",
        "blood pressure (hypotension or hypertension status)",
        "presence of parenchymal lung disease",
        "presence of bronchopulmonary dysplasia",
        "concurrent phosphodiesterase type 5 (PDE5) inhibitor therapy",
        "concurrent therapy with prostacyclin or its analogues",
        "use of doxazosin",
        "nitrates",
        "or cancer therapy",
        "use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers",
        "nursing status",
        "previous tadalafil therapy",
        "allergy to excipients",
        "participation in other clinical trials",
        "ability to take orally administered tablets or suspension",
        "diagnosis of Down syndrome"
      ]
    },
    "processed-gen-response": "Age, sex, weight, height, diagnosis of PAH, type of PAH (idiopathic, related to connective tissue disease, related to anorexigen use, associated with surgical repair), mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure, pulmonary vascular resistance (PVR), World Health Organization (WHO) functional class, use of endothelin receptor antagonist (ERA), aspartate transaminase (AST) levels, alanine transaminase (ALT) levels, use of conventional PAH medication, pregnancy status (for females of childbearing potential), history of left-sided heart disease, renal function (creatinine clearance), presence of retinal disorder, blood pressure (hypotension or hypertension status), presence of parenchymal lung disease, presence of bronchopulmonary dysplasia, concurrent phosphodiesterase type 5 (PDE5) inhibitor therapy, concurrent therapy with prostacyclin or its analogues, use of doxazosin, nitrates, or cancer therapy, use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers, nursing status, previous tadalafil therapy, allergy to excipients, participation in other clinical trials, ability to take orally administered tablets or suspension, diagnosis of Down syndrome."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline 6 Minute Walk Distance, WHO Functional Class, Pulmonary Artery Pressure, Pulmonary Vascular Resistance, Pulmonary Artery Wedge Pressure, Concomitant PAH Medications,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "6 Minute Walk Distance",
          "Baseline 6 Minute Walk Distance"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "WHO Functional Class",
        "Pulmonary Artery Pressure",
        "Pulmonary Vascular Resistance",
        "Pulmonary Artery Wedge Pressure",
        "Concomitant PAH Medications"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Baseline 6 Minute Walk Distance, WHO Functional Class, Pulmonary Artery Pressure, Pulmonary Vascular Resistance, Pulmonary Artery Wedge Pressure, Concomitant PAH Medications"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Weight, Height, Body Mass Index, WHO Functional Class, Pulmonary Artery Pressure, Pulmonary Vascular Resistance, Aspartate Transaminase, Alanine Transaminase, ERA Dose, Conventional PAH Medication Dose.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "6 Minute Walk Distance",
          "6 Minute Walk Distance"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Weight",
        "Height",
        "Body Mass Index",
        "WHO Functional Class",
        "Pulmonary Artery Pressure",
        "Pulmonary Vascular Resistance",
        "Aspartate Transaminase",
        "Alanine Transaminase",
        "ERA Dose",
        "Conventional PAH Medication Dose"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Weight, Height, Body Mass Index, WHO Functional Class, Pulmonary Artery Pressure, Pulmonary Vascular Resistance, Aspartate Transaminase, Alanine Transaminase, ERA Dose, Conventional PAH Medication Dose."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, weight, height, race, ethnicity, WHO functional class, PAH diagnosis (idiopathic, related to connective tissue disease, related to anorexigen use, associated with surgical repair of congenital systemic to pulmonary shunt), ERA use, conventional PAH medication use, aspartate transaminase (AST), alanine transaminase (ALT), creatinine clearance (CC), left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVSF), pulmonary artery wedge pressure (PAWP), pulmonary vascular resistance (PVR), mean pulmonary artery pressure (mPAP).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "6 Minute Walk Distance",
          "WHO functional class"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "PAH diagnosis (idiopathic, related to connective tissue disease, related to anorexigen use, associated with surgical repair of congenital systemic to pulmonary shunt)",
        "ERA use",
        "conventional PAH medication use",
        "aspartate transaminase (AST)",
        "alanine transaminase (ALT)",
        "creatinine clearance (CC)",
        "left ventricular ejection fraction (LVEF)",
        "left ventricular shortening fraction (LVSF)",
        "pulmonary artery wedge pressure (PAWP)",
        "pulmonary vascular resistance (PVR)",
        "mean pulmonary artery pressure (mPAP)"
      ]
    },
    "processed-gen-response": "Age, sex, weight, height, race, ethnicity, WHO functional class, PAH diagnosis (idiopathic, related to connective tissue disease, related to anorexigen use, associated with surgical repair of congenital systemic to pulmonary shunt), ERA use, conventional PAH medication use, aspartate transaminase (AST), alanine transaminase (ALT), creatinine clearance (CC), left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVSF), pulmonary artery wedge pressure (PAWP), pulmonary vascular resistance (PVR), mean pulmonary artery pressure (mPAP)."
  }
}